OTC Monograph User Fee Goals Document Beats Authorization To Finish Line
This article was originally published in The Pink Sheet
Executive Summary
While still awaiting the addition of OTC user fees to pending user fee authorization, and congressional approval of the overall package, FDA has developed guidelines closely tracking Sens. Isakson and Casey's OTC proposal. FDA plans a webinar to update industry on how OTC user fees would work.
You may also be interested in...
Timers Start Ticking At US FDA In A Month For An Even Dozen OTC Monograph Meeting Requests
CDER Office of Nonprescription Drugs already accepts requests but won’t start responding until FY2023 begins on 1 October, also the start of FDA’s first year meeting with firms developing monograph changes and evaluating submitted proposals under deadlines included in program overhaul Congress authorized in 2020.
OTC Monograph Reform Emerges In Senate Proposal For Covid-19 Economic Relief
Senate pandemic economic relief legislation legislation would reform monograph drug program and allow purchases of OTC drugs with pre-tax health savings accounts. But lingering disagreements between Democrats and Republicans blocked the Senate's passage of the bill on 25 March.
FDA Gives Congress Reprieve On Deadline For Passing User Fee Bill
Commissioner Gottlieb says agency won't issue layoff notices 'unless and until Sept. 30 passes without reauthorization.'